A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Código QR

A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Vera K Schmit-Eilenberger Augenklinik Städtisches Klinikum, Karlsruhe, Baden-Württemberg, Germany Background: Iluvien® is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 µg/d fluocinolone acetonide [FAc]) indicated in Europe for the treatm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Schmit-Eilenberger VK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/39bc8d8ac6194779b7d5ad39b7a49669
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon H, et al.
Publicado: (2017)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
por: Adán A, et al.
Publicado: (2020)

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
por: Haritoglou C, et al.
Publicado: (2013)

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
por: Massin P, et al.
Publicado: (2016)

Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal).
por: Francesco Saverio Sorrentino, et al.
Publicado: (2021)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho J, et al.
Publicado: (2019)

Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
por: Marey HM, et al.
Publicado: (2011)

EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
por: Ume Sughra, et al.
Publicado: (2021)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard Jr JD, et al.
Publicado: (2012)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Off-label use of intravitreal triamcinolone acetonide for diabetic macular edema in a pregnant patient
por: Fazelat A, et al.
Publicado: (2011)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
por: Kiire CA, et al.
Publicado: (2015)

Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel PU, et al.
Publicado: (2015)

Intravitreal gas injection for the treatment of diabetic macular edema
por: McHugh D, et al.
Publicado: (2011)

Macular sensitivity and morphology after intravitreal injection of triamcinolone acetonide for macular edema secondary to central retinal vein occlusion
por: Mimura T, et al.
Publicado: (2012)

Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
por: Mushtaq B, et al.
Publicado: (2021)

Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
por: Steeples LR, et al.
Publicado: (2021)

Letter to the editor: dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Hall J
Publicado: (2015)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
por: Pacella E, et al.
Publicado: (2013)

Letter to the Editor Regarding the “Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis” Article [Letter]
por: Taylor K, et al.
Publicado: (2020)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Guti&eacute;rrez, et al.
Publicado: (2008)

Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
por: Cebeci Z, et al.
Publicado: (2015)

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein occlusion
por: Tsai MJ, et al.
Publicado: (2018)

Assessment of Suprachoroidal Injection of Triamcinolone Acetonide in Cases of Diabetic Macular Edema
por: Mahmoud Samy Yousef, et al.
Publicado: (2021)

Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
por: Matteo Fallico, et al.
Publicado: (2021)

Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization
por: Figueira J, et al.
Publicado: (2021)

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye
por: Ren Aoki, et al.
Publicado: (2021)

Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex&reg;) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
por: Chan A, et al.
Publicado: (2011)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim M, et al.
Publicado: (2013)

Intravitreal triamcinolone for intraocular inflammation and associated macular edema
por: Steven M Couch, et al.
Publicado: (2008)

Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy
por: Tlucek PS, et al.
Publicado: (2013)

Primary treatment of diabetic macular edema
por: Tushar M Ranchod, et al.
Publicado: (2009)

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
por: Elbarky AM
Publicado: (2020)

Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
por: Zola M, et al.
Publicado: (2017)

Combined vitrectomy and intravitreal injection versus combined laser and injection for treatment of intractable diffuse diabetic macular edema
por: Saeed AM
Publicado: (2013)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
por: Jeon S, et al.
Publicado: (2014)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
por: Veritti D, et al.
Publicado: (2021)

OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion
por: Kwang-Eon Choi, et al.
Publicado: (2019)